Nimodipin Altan (Nimodipine)

Nimodipine, the active ingredient in Nimodipin Altan, is a calcium channel blocker presented as a sterile solution for injection for intravenous use. It acts as a cerebral vasodilator and is indicated for the prevention of cerebral vasospasm after subarachnoid hemorrhage.

GNH USA supplies Nimodipin Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU pharmacopoeial standards and is manufactured under GMP conditions and is available for bulk and kit formats.

Nimodipine is used primarily in the management of cerebrovascular complications, especially cerebral vasospasm.

Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the risk of delayed ischemic neurological deficits.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hypotension: mild to moderate drop in blood pressure. - Headache: transient cephalic discomfort. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with skin reddening. - Dizziness: sensation of light‑headedness. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall requiring intervention. - Myocardial infarction: rare cardiac ischemic events. - Allergic reactions: rash, urticaria, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin eruption. - Hepatic dysfunction: elevated liver enzymes. - Hemorrhagic complications: rare bleeding events.

Careful assessment and monitoring are required before and during therapy. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: use with caution and observe liver enzymes. - Concomitant antihypertensives: monitor blood pressure closely. - Pregnancy: only if clearly needed, after risk‑benefit evaluation. - Elderly patients: observe for increased sensitivity to hypotensive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nimodipine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma nimodipine levels. - Other calcium channel blockers: additive hypotensive effect can be dangerous.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce nimodipine exposure. - Beta‑blockers: potential for enhanced bradycardia. - Diuretics: increased risk of hypotension. - Antihypertensive agents: may require dose adjustments.